TC
ZVRA icon

TFS Capital’s Zevra Therapeutics ZVRA Stock Holding History

TFS Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-837
Closed -$53K – 1011
2016
Q2 		$53K Sell
837
-1,217
-59% -$200K 0.01% 912
2016
Q1 		$476K Buy
+2,054
New +$497K 0.07% 462

Other funds holding ZVRA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TFS Capital's ZVRA Position: Q3 2016 in Review

TFS Capital sold out of Zevra Therapeutics (ZVRA) in Q3 2016, closing a stake of 837 shares — an estimated $53K sold.

TFS Capital first reported a position in ZVRA in Q1 2016 and held it in 2 quarters. The position peaked at $476K in Q1 2016. 40 funds tracked by Wall St. Rank hold ZVRA as of Q3 2016.

  • TFS Capital reported no remaining Zevra Therapeutics position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 837 Zevra Therapeutics shares in Q3 2016, an estimated $53K.
  • TFS Capital first reported a position in Zevra Therapeutics in Q1 2016 and held it in 2 quarters.
  • TFS Capital's Zevra Therapeutics position peaked at $476K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.